AUG 18, 2026 · JOURNAL ARTICLE
Zidesamtinib (Jideytro®): a new selective, brain-penetrant ROS1 inhibitor approved for the treatment of ROS1-positive non-small cell lung cancer
Medicinal Chemistry Research
FDA accelerated approval of zidesamtinib for ROS1-positive NSCLC in treatment-experienced patients, based on phase 1/2 trial data showing durable efficacy and manageable safety.
Reported
FDA approval dateJuly 22, 2026
Approved dose100 mg once daily